Immunexus

Immunexus is an Australian biotechnology company specializing in the development of a proprietary platform for the rapid generation of bispecific antibodies. The company's technology enables the conversion of existing, clinically validated monoclonal antibodies into bispecific formats with minimal re-engineering, aiming to enhance therapeutic efficacy in oncology. By utilizing off-the-shelf antibodies, Immunexus seeks to accelerate the creation of multi-specific biologics that can simultaneously target multiple disease pathways. The platform is specifically designed to address industry-wide challenges related to the manufacturing complexity and stability of bispecific molecules. Currently in the pre-clinical stage, the company focuses on advancing its internal pipeline and establishing strategic partnerships with global pharmaceutical firms.